A 505(j) application is an abbreviated new drug application (ANDA) that contains information to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics and intended use, among other things, to a previously approved …

What is Section 505 of the Federal Food Drug and Cosmetic Act?

Section 505(o)(4) authorizes FDA to require certain drug and biological product application holders to make safety-related labeling changes based on new safety information that becomes available after approval of the drug or biological product.

What kind of application can be submitted as a 505 b )( 2 application?

A 505(b)(2) application is a new drug application (NDA) described in section 505(b)(2) of the Act. It is submitted under section 505(b)(1) of the Act and approved under section 505(c) of the Act. This guidance also provides further information and amplification regarding FDA’s regulations at 21 CFR 314.54.

What is 505b application?

A 505(b)(2) application is an NDA that contains full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference or use, including, for …

What is 505b pathway?

The 505 (b)(2) pathway provides manufacturers who have certain types of drugs with an opportunity to acquire FDA approval without performing all the work that’s required with an NDA. These drugs are not strictly generics, but are often not entirely novel new molecular entities either.

What are the examples of changes to approved drug products for which 505 b )( 2 application should be submitted?

• Change in the route of administration.
• Conversion to lower or higher strength.
• Change in the route of administration of dosage form or dosage regimen.
• Change in the formulation.

What is a 505j?

A 505(j) application is an abbreviated new drug application (ANDA) that contains information to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics and intended use, among other things, to a previously approved …

Is 505b2 an NDA?

The 505(b)(2) new drug application (NDA) is one of three U.S. Food and Drug Administration (FDA) drug approval pathways and represents an appealing regulatory strategy for many clients.

What is hybrid NDA?

Hybrid Medicines. and 505(b)(2) NDA. Approval Pathways. Hybrid medicines are drugs based on a generic molecule and have a different route of administration, format, strength, or indication from the original reference product.

What is a BLA filing?

A biologics license application (BLA) is a request to distribute a biologic across states. It generally is submitted after an Investigational New Drug (IND) or an Investigational Device Exemption (IDE) and after the appropriate studies have been conducted.

Article first time published on

What is breakthrough therapy status?

A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.

What does the Hatch Waxman Act do?

Broadly speaking, the Hatch-Waxman Act provides incentives for generic drug companies to challenge patents owned by innovators, and it gives generics a research exemption that allows them to develop generic drugs while patents for the brand are still in force — without being liable for infringement.

Which is an orphan drug?

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.

What is a right of reference FDA?

Right of reference or use: “the authority to rely upon, and otherwise use, an investigation for the purpose of obtaining approval of an application, including the ability to make available the underlying raw data from the investigation for FDA audit, if necessary” (21 CFR 314.3(b)).

What are the differences between an NDA and an ANDA application?

NDA means a New Drug Application. … If the NDA is approved, then the product may be marketed in the United States. ANDA means Abbreviated New Drug Application. An abbreviated new drug application (ANDA) contains data that, when submitted to the FDA, provides for the review and ultimate approval of a generic drug product.

What is the difference between Ind NDA and ANDA?

In short, IND application is to declare to the authorities for clinical trials; NDA application is to report to the authorities for drug registration and marketing; and ANDA application refers to the application for registration and marketing of generic drugs.

What is a generic equivalent drug?

According to the US Food and Drug Administration (FDA), a generic drug is identical—or bioequivalent—to a brand-name drug in “dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.” This statement seems straightforward enough.

When can you file ANDA?

Generic pharmaceutical companies will typically file an ANDA when the patent protection period of a brand-name drug is about to expire.

Why is the generic drug application submitted to the FDA called abbreviated?

Generic drug applications are termed “abbreviated” because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, generic applicants must scientifically demonstrate that their product is performs in the same manner as the innovator drug.

What is a desi product?

FDA’s final DESI determination classifies a drug as either effective for one or more of its labeled indications or lacking substantial evidence of effectiveness for one or more of its labeled indications. Most DESI proceedings have been closed and FDA’s findings have been published in the Federal Register.

What is IND and BLA?

Investigational New Drug (IND) Application. New Drug Application (NDA) Therapeutic Biologics Applications (BLA)

Who is DMF?

INTRODUCTION. A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.

How many types of Inda are there?

Three types of meetings may be held between sponsors and FDA: Type A meeting; Type B meeting; and. Type C meeting.

What is new product exclusivity?

New Drug Product Exclusivity is provided by the Federal Food, Drug, and Cosmetic Act under section 505(c)(3)(E) and 505(j)(5)(F). Exclusivity provides the holder of an approved new drug application limited protection from new competition in the marketplace for the innovation represented by its approved drug product.

Is a BLA the same as FDA approval?

A Biologics License Application, or BLA, is FDA’s standard “full approval” mechanism for biological products, including therapeutics and vaccines. … A company receiving a BLA for their product can introduce the product into interstate commerce and market it for its approved uses.

Is BLA same as NDA?

An NDA is an application to permit the sale and marketing of a new drug in the United States. … Drugs that are approved via an NDA pathway are regulated under Section 505 of the Food, Drug, & Cosmetics (FD&C) Act. A BLA is a request to introduce, or deliver for introduction, a biological product into interstate commerce.

How long does BLA approval take?

Review Timeline As per the Prescription Drug User Fee Act (PDUFA), the FDA agreed to review the majority of BLAs within 10 months of 60 day filing and for the priority submissions it has been cut down to 6 months of 60 day filing date.

What is the success rate of the breakthrough therapy?

Based on our recent analysis, approximately 3 in 10 structurally novel small molecule NTDs achieved breakthrough status compared with just 1 in 10 non-structurally novel small molecule NTDs. That means structurally novel drugs have been more than twice as likely to be granted BTD status by the FDA.

What is the biggest difference between standard approval of a new drug application and accelerated approval?

The difference is that drugs granted accelerated approval must promptly conduct post-marketing confirmatory trials to verify the clinical benefit (as early as underway at the time the marketing application is submitted).

What is Fast Track status FDA?

Fast track is a designation by the United States Food and Drug Administration (FDA) of an investigational drug for expedited review to facilitate development of drugs which treat a serious or life-threatening condition and fill an unmet medical need. Fast Track designation must be requested by the drug company.

What is Paragraph IV?

Paragraph IV Patent Certifications. … This 30-month postponement, commonly referred to as the “30-month stay,” gives the brand product sponsor and patent holder a prescribed amount of time to assert patent rights in court before a generic competitor is approved and can market the drug.